ADA 2024 Standards of Care: Cardiorenal Protection Updates

Abstract

The 2024 updates to the American Diabetes Association (ADA) Standards of Care reflect a paradigm shift from purely glycemic control toward comprehensive cardiorenal-kidney-metabolic (CKM) risk management in type 2 diabetes (T2D). 

The cornerstone of these recommendations is the early, integrated use of therapies with proven organ-protective effects, regardless of baseline hemoglobin A1c (HbA1c) levels. The guidelines strongly reinforce Class I recommendations for Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) for patients with established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure (HF). 

Key updates include new guidance on classifying and managing CKM syndrome, integrating Nonsteroidal Mineralocorticoid Receptor Antagonists (nsMRAs) such as finerenone into the CKD management pathway, and emphasizing the importance of team-based, multidisciplinary care. 

These updates mandate that clinicians prioritize evidence-based agents to mitigate cardiorenal morbidity and mortality, thereby altering standard therapeutic algorithms for T2D.

Introduction

Evolution of Diabetes Management: From Glycemia to Cardiorenal Outcomes

Type 2 diabetes mellitus (T2D) represents a massive global health challenge, characterized by hyperglycemia resulting from progressive insulin resistance and beta-cell dysfunction.

Historically, the primary therapeutic focus was on achieving stringent glycemic targets to mitigate microvascular complications, a strategy validated by landmark studies like the UKPDS. However, cardiovascular disease (CVD) and chronic kidney disease (CKD) remain the leading causes of morbidity and mortality among individuals with T2D. 

The last decade has fundamentally reshaped this therapeutic approach, transitioning the standard of care from a glucose-centric model to a cardiorenal-centric model. The 2024 American Diabetes Association (ADA) Standards of Care reflect this critical pivot, formalizing the need to address the interrelated pathology known as Cardiorenal-Kidney-Metabolic (CKM) syndrome through early, preventative strategies.

This introduction sets the context for the detailed review of the ADA’s strengthened guidelines on utilizing agents with proven cardioprotective and renoprotective benefits, specifically Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA). 

The goal is to maximize patient longevity and quality of life by preventing, rather than just treating, the major macrovascular and renal consequences of T2D.

Integrated Cardiorenal-Kidney-Metabolic (CKM) Care

The ADA 2024 Standards of Care introduce and formalize the concept of Cardiorenal-Kidney-Metabolic (CKM) Syndrome to underscore the complex, bidirectional risk relationship between type 2 diabetes (T2D), obesity, cardiovascular disease (CVD), and chronic kidney disease (CKD). 

This framework mandates a holistic, risk-based management approach rather than treating each condition in isolation.

Defining the CKM Syndrome and Risk Stratification

The CKM syndrome is defined by the presence of T2D or metabolic syndrome plus cardiovascular risk enhancers, CKD, or established CVD. The ADA now recommends a structured four-stage risk classification to guide therapeutic intensity:

• Stage 0: No CKM risk factors (excluding overweight/obesity).
  
  
• Stage 1: At risk (overweight/obesity and metabolic dysfunction, no T2D).
  
  
• Stage 2: Established T2D or metabolic syndrome, without established CVD or CKD.
  
  
• Stage 3: Established T2D or metabolic syndrome, with subclinical or established CVD or moderate to high-risk CKD.
  
  
• Stage 4: Established T2D or metabolic syndrome, with very high-risk CVD (e.g., prior myocardial infarction, heart failure) or end-stage kidney disease (ESKD).
  
  

This stratification is designed to shift clinical focus towards early primary prevention in Stages 1 and 2, and aggressive secondary and tertiary prevention using organ-protective therapies in Stages 3 and 4.

Guideline-Driven Assessment: eGFR and Albuminuria Screening

Accurate and timely diagnosis of early CKD is paramount within the CKM care model, as microalbuminuria often precedes a significant decline in glomerular filtration rate (eGFR). The ADA guidelines strongly reaffirm the Class I recommendation for mandatory annual screening of all patients with diabetes for CKD, emphasizing two critical metrics:

1. Estimated Glomerular Filtration Rate (eGFR): Measured using a validated creatinine-based equation, this determines the severity of kidney function impairment.
   
   
2. Urine Albumin-to-Creatinine Ratio (UACR): A UACR of ≥ 30 mg/g (or ≥ 3 mg/mmol) indicates albuminuria, a key predictor of both CKD progression and cardiovascular events. Persistent albuminuria is a strong signal for the immediate initiation or intensification of protective therapies, particularly SGLT2 inhibitors and GLP-1 receptor agonists, in conjunction with optimized Renin-Angiotensin-Aldosterone System (RAAS) blockade.
   
   

The combined use of eGFR and UACR allows for precise staging of kidney disease (KDIGO classification) and ensures the timely application of drugs proven in major cardiorenal outcome trials.

Pharmacologic Pillars of Organ Protection

The ADA 2024 Standards of Care solidify the evidence-based prioritization of pharmacologic agents that confer robust cardiorenal protection, moving them to the forefront of initial and ongoing therapy for individuals with Type 2 Diabetes (T2D) who have or are at high risk for cardiovascular or renal complications.

SGLT2 Inhibitors: Class I Recommendations for Heart Failure and CKD

Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) are given a Class I, Level A recommendation across multiple cardiovascular and renal indications, positioning them as essential components of T2D management. These agents provide systemic benefits beyond glycemic control, acting primarily by reducing glucose reabsorption in the proximal tubule and exerting positive effects on hemodynamics, inflammation, and myocardial energetics.

• Evidence Base: Major Trials (DAPA-CKD, EMPA-KIDNEY)
  The foundational evidence for SGLT2i includes major, multinational Randomized Controlled Trials (RCTs).
  For Diabetic Kidney Disease (DKD) and non-diabetic CKD, trials like DAPA-CKD (Dapagliflozin) and EMPA-KIDNEY (Empagliflozin) demonstrated significant reductions in the composite outcome of sustained eGFR decline, end-stage kidney disease (ESKD), or renal death. In DAPA-CKD, the hazard ratio for the primary composite endpoint was 0.61 (95% CI, 0.51 to 0.72; P<0.001).
  For Heart Failure (HF), regardless of left ventricular ejection fraction (LVEF), SGLT2i reduced hospitalizations for HF and cardiovascular death, established by trials such as DAPA-HF, EMPEROR-Reduced, and EMPEROR-Preserved.
  
  
• Practical Considerations for Initiation and Continuation (eGFR thresholds)
  SGLT2i initiation is now recommended down to an eGFR as low as 20 mL/min/1.73 m² for cardiorenal protection (specifically based on EMPA-KIDNEY data).
  While the glucose-lowering effect diminishes at lower eGFRs, the profound renal and cardiovascular benefits persist, supporting continued use even in advanced CKD.
  
  

GLP-1 Receptor Agonists: Focus on ASCVD and Kidney Endpoints

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) are also strongly recommended, particularly for patients with T2D and established Atherosclerotic Cardiovascular Disease (ASCVD) or multiple ASCVD risk factors. GLP-1RA primarily enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes weight loss, while also demonstrating independent anti-atherosclerotic properties.

• Evidence Base: Major Trials (e.g., FLOW, SELECT)
  Cardiovascular Outcome Trials (CVOTs) for various long-acting GLP-1RAs (e.g., liraglutide, semaglutide, dulaglutide) consistently showed superiority in reducing major adverse cardiovascular events (MACE).
  The SELECT trial (Semaglutide) extended this benefit to individuals with pre-existing CVD but without diabetes, showing a 20% reduction in MACE (HR 0.80; 95% CI, 0.72 to 0.90; P<0.001).
  Furthermore, the recent FLOW trial (Semaglutide) confirmed a significant reduction in kidney outcomes. These data reinforce the Class I, Level A recommendation for GLP-1RA use in high-risk populations.
  
  
• Role in Combination Therapy with SGLT2i
  The ADA guidelines support the combination of SGLT2i and GLP-1RA as a highly effective strategy to achieve maximal cardiorenal and metabolic protection.
  Given their complementary mechanisms of action, this combination provides superior risk reduction compared to monotherapy, especially for patients with concurrent high ASCVD risk, CKD, or heart failure.
  
  

Nonsteroidal Mineralocorticoid Receptor Antagonists (nsMRAs)

Nonsteroidal Mineralocorticoid Receptor Antagonists (nsMRAs), particularly finerenone, are a key addition to the therapeutic armamentarium for T2D and CKD, targeting chronic inflammation and fibrosis distinct from RAAS inhibition.

• Finerenone: Evidence for Reduced CV Events and CKD Progression (FIDELIO-DKD, FIGARO-DKD)
  The FIDELIO-DKD and FIGARO-DKD trials established finerenone’s efficacy in patients with T2D and CKD (defined by albuminuria and eGFR ≥ 25 mL/min/1.73 m²), despite receiving maximum tolerated doses of RAAS inhibitors.
  The nsMRA significantly reduced the risk of CKD progression and cardiovascular events, including heart failure hospitalization, demonstrating an additive protective effect when layered upon standard care.
  
  
• Appropriate Patient Selection (ACR and eGFR criteria)
  Finerenone is specifically recommended for patients with T2D and CKD who have albuminuria (UACR ≥ 30 mg/g) and an eGFR ≥ 25 mL/min/1.73 m² and are already treated with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB).
  The primary safety consideration remains hyperkalemia, requiring baseline and ongoing serum potassium monitoring.
  
  

Management of Concurrent Cardiovascular Comorbidities

The integrated Cardiorenal-Kidney-Metabolic (CKM) approach outlined by the ADA 2024 Standards of Care necessitates the aggressive and guideline-directed management of cardiovascular comorbidities, recognizing that diabetes is a powerful accelerator of both atherosclerotic and non-atherosclerotic heart disease.

Atherosclerotic Cardiovascular Disease (ASCVD) Risk Reduction

For patients with Type 2 Diabetes (T2D), the primary strategy for reducing ASCVD events (myocardial infarction, stroke, cardiovascular death) involves a multifaceted approach targeting lipids, blood pressure, and thrombosis, layered upon the use of organ-protective agents (GLP-1RA and SGLT2i).

• Lipid Management: High-intensity statin therapy remains the cornerstone for patients with established ASCVD or those aged 40–75 years with multiple ASCVD risk factors. The guidelines strongly endorse the use of non-statin therapies, such as PCSK9 inhibitors or ezetimibe, when LDL-C targets (LDL-C < 55  mg/dL for very high-risk individuals) are not met with maximum tolerated statin therapy.
  
  
• Hypertension Control: Blood pressure targets are individualized, but generally aim for <130/80  mmHg for most adults with T2D. Renin-Angiotensin-Aldosterone System (RAAS) inhibitors (ACEI/ARB) are the preferred first-line agents, especially in the presence of albuminuria, due to their independent renoprotective effects.
  
  
• Antiplatelet Therapy: Low-dose aspirin (75–162 mg/day) is indicated for secondary prevention in patients with a history of ASCVD. For primary prevention, the decision is individualized based on a high ASCVD risk and low bleeding risk. In certain high-risk post-ACS or polyvascular disease scenarios, dual antiplatelet therapy (DAPT) or the addition of low-dose rivaroxaban may be considered, consistent with ESC and AHA/ACC guidelines.
  
  

Heart Failure with Reduced and Preserved Ejection Fraction (HFrEF, HFpEF)

Heart failure (HF) is the most common and often earliest cardiovascular complication of T2D, frequently preceding clinical ASCVD events. The ADA guidelines are now fully aligned with cardiology recommendations, emphasizing the role of SGLT2 inhibitors as a foundational therapy.

• SGLT2 Inhibitors (SGLT2i): These agents are now considered a Class I, Level A standard of care for patients with T2D and HFrEF (LVEF ≤ 40%) and are strongly recommended for HFpEF (LVEF > 40%). The benefit is independent of the presence of T2D or other established guideline-directed medical therapy (GDMT).
  
  
• Sequential Quadruple Therapy: For HFrEF in patients with T2D, the recommended GDMT should ideally include an SGLT2i alongside the other three pillars: a beta-blocker, a RAAS inhibitor (ACEI/ARB or ARNI), and a Mineralocorticoid Receptor Antagonist (MRA) (spironolactone or eplerenone, or the nsMRA finerenone in specific CKD cases).
  
  

The goal is rapid, sequential implementation of these four classes of medications to reduce volume overload, mitigate neurohormonal activation, and attenuate myocardial remodeling and fibrosis, which are amplified in the diabetic state.

Special Populations / Comorbidities

The comprehensive nature of the ADA 2024 Standards of Care extends to providing tailored guidance for vulnerable patient subsets, acknowledging that management must be individualized based on age, fragility, and specific coexisting conditions.

Geriatric Populations and Frailty

Management of T2D in older adults (≥ 65 years) requires a nuanced approach that balances the benefits of cardiovascular protection against the risks of polypharmacy, hypoglycemia, and potential adverse effects of certain agents (e.g., volume depletion with SGLT2i).

• Goals: Glycemic targets are often relaxed (HbA1c < 7.5% to 8.5%) depending on cognitive function, life expectancy, and comorbidity burden. The priority shifts from strict HbA1c control to preventing hypoglycemia (especially with insulin or sulfonylureas) and maximizing functional status.
  
  
• Cardiorenal Agents: The use of SGLT2 inhibitors and GLP-1 receptor agonists remains strongly recommended in robust older adults due to their established CV benefits and low risk of hypoglycemia. However, caution is necessary regarding volume status and potential for genital mycotic infections with SGLT2i. The potential for weight loss with GLP-1RA should be assessed carefully in frail patients, where unintentional weight loss is detrimental.
  
  

Type 1 Diabetes (T1D) and CKD

While the primary focus of cardiorenal guidelines is often on T2D, patients with Type 1 Diabetes (T1D) are also at high risk for diabetic kidney disease (DKD) and premature ASCVD.

• Renal Protection: The use of RAAS inhibitors (ACEI/ARB) is the established first-line therapy to slow DKD progression in T1D patients with albuminuria.
  
  
• SGLT Inhibitor Use: Recent evidence and position statements support the consideration of SGLT inhibitors (SGLT1/2i and SGLT2i) as an adjunct to insulin therapy in T1D, primarily for cardiorenal risk reduction. This use requires careful titration and patient education due to an increased risk of euglycemic diabetic ketoacidosis (eDKA). This therapeutic decision should be made by specialized endocrinology or cardiorenal teams.
  
  

Chronic Kidney Disease (CKD) Management Nuances

The integration of finerenone into the CKD care algorithm provides an additional layer of protection beyond RAAS blockade and SGLT2i.

• Sequence of Therapy: For a patient with T2D, an eGFR ≥ 25  mL/min/1.73 m², and albuminuria (UACR ≥ 30  mg/g), the optimal sequence involves:
  
  
  1. Maximized RAAS inhibitor (ACEI/ARB) therapy.
     
     
  2. Addition of an SGLT2 inhibitor.
     
     
  3. If albuminuria persists, the addition of finerenone is indicated to further reduce cardiorenal risk, with careful monitoring of serum potassium.
     
     

Clinical Practice Summary: Implementation & Key Takeaways

The ADA 2024 Standards of Care deliver a decisive mandate: the management of Type 2 Diabetes (T2D) must be centered on comprehensive Cardiorenal-Kidney-Metabolic (CKM) risk reduction. Implementation of these guidelines requires a fundamental shift in prescribing behavior, prioritizing agents with proven organ-protective benefits early in the disease course.

Practice Highlights: A Tool-Kit for Prescribing Clinicians

Controversies and Emerging Data

While the evidence for SGLT2 inhibitors and GLP-1 receptor agonists is overwhelming, several areas remain subject to ongoing research and clinical debate:

1. Optimal Sequencing: The exact sequence of introducing SGLT2i versus GLP-1RA when both are indicated for primary prevention (e.g., in high-risk patients without established events) is not rigidly defined and may depend on individual patient factors, such as the dominance of ASCVD risk versus heart failure risk, or the need for weight management.
   
   
2. Triple Therapy for CKD: The combined use of a RAAS Inhibitor, an SGLT2 Inhibitor, and Finerenone is now the guideline-recommended maximal medical therapy for many patients with T2D and progressive CKD. Managing the potential increased risk of hyperkalemia while maximizing renoprotection remains a critical practical challenge.
   
   
3. CKM Syndrome in Non-Diabetic Patients: The emerging CKM risk framework highlights that the cardiorenal benefits of SGLT2i and GLP-1RA, demonstrated in trials like SELECT and EMPEROR-Preserved, extend to non-diabetic populations, signaling a potential future expansion of these agents beyond traditional diabetes care.
   
   

The core takeaway is that in the era of CKM care, pharmacotherapy for T2D is no longer dictated by HbA1c alone but by an urgent need to prevent catastrophic cardiorenal outcomes through the mandatory, early use of organ-protective drug classes.